Natera Inc. stocks have been trading up by 20.85 percent, driven by strong clinical data fueling bullish investor sentiment.
Click Here for a Millionaire's POV on Trading NTRA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Q2 revenue came in at $752.8M, far above the $661.2M consensus, signaling much stronger test demand than the Street expected.
- The company posted a Q2 loss of $0.47 per share, slightly better than the expected $0.49 loss, showing gradual progress on margins.
- Full-year 2026 revenue guidance was raised to $2.85B–$2.91B, above the roughly $2.8B consensus, pointing to stronger growth momentum.
- Shares surged more than 12% in after-hours trading following the earnings beat and outlook raise, resetting near-term expectations.
- The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer, expanding on existing colorectal approval and supporting longer-term oncology growth.
Quick Financial Overview
Natera Inc. (NTRA) just printed the kind of quarter that forces the market to reprice the story. Q2 revenue of $752.8M versus $661.2M expected is a big upside surprise and confirms strong demand across its testing platforms, especially oncology. The EPS loss of $0.47, slightly better than the $0.49 loss expected, keeps Natera in the red but shows incremental efficiency as scale builds.
On the balance sheet and cash flow side, the picture is typical high-growth diagnostics: heavy revenue growth with negative profitability metrics, but improving cash generation. Trailing revenue of about $2.31B and revenue growth above 40% over three and five years reflect fast top-line expansion. Yet margins are still negative, with an EBIT margin near -13.1% and return on equity also well below zero, meaning traders are paying for growth, not earnings, right now.
More Breaking News
- DraftKings Stock Wobbles As Guidance And Growth Impress
- UWMC Stock Whipsaws As Capital Deal Fights Steep Selloff
- PATH Stock Grinds Higher As Bulls Test New Range
- RKT Stock Slides As Guidance Tempers Rocket Companies’ Breakout Quarter
Valuation is rich, with a price-to-sales ratio around 15.73 and price-to-book above 22, backed by an enterprise value of roughly $38.23B. However, leverage is modest, with total debt-to-equity near 0.13 and a current ratio around 3, giving Natera Inc. some balance sheet flexibility. On the chart, the weekly move from $265.38 to a $330 high and a recent close around $322.10 shows a sharp post-earnings breakout. Intraday action around $310–$323 shows strong bids on dips, with shallow pullbacks getting bought quickly, typical of a momentum continuation setup after a fresh catalyst.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.